Business News
Biotech Posts Weak Performance in April
Despite the rise in the shares of Dendreon on the announcement that its prostate cancer therapy Provenge had finally been approved by the U.S. FDA, the biotech sector could not build on that event and turned in a lackluster performance for April 2010 with the Burrill Biotech Select Index falling 2% in the month, according to a recent biotech financial report. More...
02 Jun 2010
|
|
|
 |
|
|
|
BioResearch Industry News channel updates the reader on mergers and takeovers, on cooperative agreements and on trends in the biotech industry worldwide.
|
|
|
| LinkXpress |
|
|
|
| Featured MedBiz Market Reports |
|
|
|
| Events |
|
|
|
|
|
     
|
